Russell Frank Company’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Russell Frank Company’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$5.08M	Sell	306,254 -191,856	-39%	-$3.36M	0.01%	1318
2015 Q4	$11.1M	Buy	498,110 +2,665	+0.5%	+$51.9K	0.02%	826
2015 Q3	$9.82M	Buy	495,445 +245,667	+98%	+$7.76M	0.02%	900
2015 Q2	$8.68M	Buy	249,778 +198,269	+385%	+$6.05M	0.01%	1089
2015 Q1	$1.34M	Buy	+51,509	New	+$944K	﹤0.01%	1988
2014 Q4	–	Sell	-78	Closed	-$1K	–	3069
2014 Q3	$1K	Sell	78 -119,435	-100%	-$1.39M	﹤0.01%	2840
2014 Q2	$1.03M	Buy	119,513 +4,326	+4%	+$61.7K	﹤0.01%	2055
2014 Q1	$1.74M	Buy	115,187 +28,942	+34%	+$327K	﹤0.01%	1836
2013 Q4	$849K	Buy	86,245 +78,898	+1,074%	+$426K	﹤0.01%	2141
2013 Q3	$25K	Buy	7,347 +7,126	+3,224%	+$18.8K	﹤0.01%	3225
2013 Q2	$1K	Buy	+221	New	+$530	﹤0.01%	3291

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Russell Frank Company's HZNP Position: Q1 2016 in Review

Russell Frank Company reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 39% in Q1 2016, selling an estimated $3.36M and leaving 306,254 shares worth $5.08M. The position accounts for 0.01% of the portfolio, ranked #1318.

Russell Frank Company first reported a position in HZNP in Q2 2013 and has held it in 11 quarters since. The position peaked at $11.1M in Q4 2015. 196 funds tracked by Wall St. Rank hold HZNP as of Q1 2016.

Russell Frank Company held 306,254 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $5.08M as of Q1 2016.
Russell Frank Company sold 191,856 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2016, an estimated $3.36M.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.01% of Russell Frank Company's portfolio in Q1 2016, its #1318 holding.
Russell Frank Company first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and has held it in 11 quarters since.
Russell Frank Company's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $11.1M in Q4 2015.
196 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.